Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Personalized sleep apnea treatment on the horizon?

NCT ID NCT04875364

Knowledge-focused Sponsor: University of California, San Diego Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study investigates why people develop obstructive sleep apnea (OSA) and whether the underlying cause affects how they respond to different treatments. Researchers will test three approaches—CPAP, a sleep medication (eszopiclone), and supplemental oxygen—in adults with OSA. The goal is to see if matching treatment to the specific cause of OSA improves outcomes like alertness and blood vessel health.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Eszopiclone, Supplemental Oxygen, Continuous Positive Airway Pressure (CPAP)
What this could lead to
If successful, this could lead to personalized treatments for sleep apnea based on an individual's underlying cause, improving effectiveness and reducing side effects.
What could go wrong
This is a mid-stage study with a moderate number of participants, so results may not apply to everyone. The treatments tested may not work for all types of sleep apnea.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

233 people

The number who actually took part.

Started

Aug 2020

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Ages 21-65 years old * Men and women with a physician diagnosis of OSA (or strongly suspected to have sleep apnea - \* see below) * BMI 20 - 35 kg/m2 Exclusion Criteria: * Pregnancy (current or planned) * Nursing * Inability to provide self-consent or complete study procedures, such as questionnaires that are only available/validated in English. * Already on effective therapy and adherent to treatment for OSA * Other known untreated sleep fragmenting disorder, such as periodic limb movement disorder, or narcolepsy * Circadian rhythm disorder * Unrevascularized coronary artery disease, angina, prior heart attack or stroke, congestive heart failure * Uncontrolled hypertension (systolic blood pressure \>160, diastolic blood pressure \>95) * Chronic lung disease requiring the use of supplemental oxygen, or with evidence of hypercapnia due to obstructive lung disease. * Presence of tracheostomy * Hospitalization within the past 90 days * Prior peptic ulcer disease, esophageal varices, or gastrointestinal bleeding (\< 5 years) * Prior gastric bypass surgery * Chronic liver disease or end-stage kidney disease * Active cancer * Allergy to any of the study drug * Regular use of medications known to affect control of breathing (opioids, sedatives/hypnotics including benzodiazepines, theophylline) * Chronically using study drug (Eszopiclone) * Active illicit substance use * Alcohol use of \>1 standard drink/night for women or \>2 standard drinks/night for men nightly alcohol use * Active smoking or vaping within the past 6 months * Psychiatric disease, other than controlled depression/anxiety * Prisoners * Subjects who are strongly suspected to have sleep apnea will be offered an overnight home sleep apnea test (HSAT) to verify OSA diagnosis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obstructive sleep apnea are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

microcephaly 6, primary, autosomal recessive obstructive sleep apnea syndrome sleep apnea syndrome sleep disorder sleep-wake disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obstructive sleep apnea Sleep Sleep apnea Sleep apnea, obstructive Sleep disorder

Contacts and locations

Locations

  • Altman Clinical and Translational Research Institute Building

    La Jolla, California, 92037, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.